Turn Therapeutics (TTRX) stock

Market cap $316MShares as of Aug 12

$10.61

+3.21%

As of Monday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score TTRX. It is too thinly traded for a fair Quality Score.

Healthcare · Biotech

NextEnd of 2026“to complete enrollment by year-end,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics.”Trial start · SEC filing · Aug 12

Follow TTRX's trial news. Pro members can get an alert when Turn Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when TTRX files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,191 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for TTRX, and how long its cash lasts

Next step the company has named

End of 2026“to complete enrollment by year-end,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics.”Trial start · SEC filing · Aug 12

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: GX-03 in ADPhase 2/3 · Recruiting · 190 people · main data estimated Jan 20, 2027 · NCT07355075

For Pro members: 3 more milestones and 27 filings.

Cash runway

The company says its cash lasts into Third Quarter of 2027 (8-K, Aug 12).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CFO Zuraiz Chaudhary bought 2,500 shares on Dec 12, 2025.

From Form 4: open-market buys and sales only.

Get an alert when Bradley Burnam buys or sells

For Pro members: every trade, and Bradley Burnam’s 19 filings and quotes.

Get an alert when TTRX files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

TTRX's latest filings

INVESTOR PRESENTATION, DATED OCTOBER 6, 20268-K, filed Oct 7
Quarterly report10-Q, filed Aug 12
4 insider filingsForm 4, filed Jun 8

39 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why TTRX isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. TTRX trades about 93,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.